Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

Lennox Jeffers, Naga Chalasani, Luis Balart, Nikolaos Pyrsopoulos, Elisabeth Erhardtsen

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Background & Aims: Activated recombinant factor VII (rFVIIa) has been shown to be effective in correcting prolonged prothrombin time (PT) in cirrhotic patients. The main objective of this study was to evaluate the effect of 4 (5, 20, 80, and 120 μg/kg) doses of rFVIIa on correction of PT and the time to achieve hemostasis in cirrhotic patients with coagulopathy who are undergoing laparoscopic liver biopsy. Methods: Seventy-one patients (parts I and II) with advanced liver disease (Child-Turcotte B or C), platelet count ≥60,000/mm3 and PT in the range of 3-15 seconds above normal were included in the study. Efficacy endpoints were normalization of PT and time to hemostasis. Results: PT was corrected to normal levels (

Original languageEnglish (US)
Pages (from-to)118-126
Number of pages9
JournalGastroenterology
Volume123
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Prothrombin Time
Liver Diseases
Biopsy
Safety
Liver
Hemostasis
Factor VIIa
Platelet Count
recombinant FVIIa

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. / Jeffers, Lennox; Chalasani, Naga; Balart, Luis; Pyrsopoulos, Nikolaos; Erhardtsen, Elisabeth.

In: Gastroenterology, Vol. 123, No. 1, 2002, p. 118-126.

Research output: Contribution to journalArticle

Jeffers, Lennox ; Chalasani, Naga ; Balart, Luis ; Pyrsopoulos, Nikolaos ; Erhardtsen, Elisabeth. / Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. In: Gastroenterology. 2002 ; Vol. 123, No. 1. pp. 118-126.
@article{e0e916827e184d9e83ff0ac73ec1478b,
title = "Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy",
abstract = "Background & Aims: Activated recombinant factor VII (rFVIIa) has been shown to be effective in correcting prolonged prothrombin time (PT) in cirrhotic patients. The main objective of this study was to evaluate the effect of 4 (5, 20, 80, and 120 μg/kg) doses of rFVIIa on correction of PT and the time to achieve hemostasis in cirrhotic patients with coagulopathy who are undergoing laparoscopic liver biopsy. Methods: Seventy-one patients (parts I and II) with advanced liver disease (Child-Turcotte B or C), platelet count ≥60,000/mm3 and PT in the range of 3-15 seconds above normal were included in the study. Efficacy endpoints were normalization of PT and time to hemostasis. Results: PT was corrected to normal levels (",
author = "Lennox Jeffers and Naga Chalasani and Luis Balart and Nikolaos Pyrsopoulos and Elisabeth Erhardtsen",
year = "2002",
doi = "10.1053/gast.2002.34164",
language = "English (US)",
volume = "123",
pages = "118--126",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy

AU - Jeffers, Lennox

AU - Chalasani, Naga

AU - Balart, Luis

AU - Pyrsopoulos, Nikolaos

AU - Erhardtsen, Elisabeth

PY - 2002

Y1 - 2002

N2 - Background & Aims: Activated recombinant factor VII (rFVIIa) has been shown to be effective in correcting prolonged prothrombin time (PT) in cirrhotic patients. The main objective of this study was to evaluate the effect of 4 (5, 20, 80, and 120 μg/kg) doses of rFVIIa on correction of PT and the time to achieve hemostasis in cirrhotic patients with coagulopathy who are undergoing laparoscopic liver biopsy. Methods: Seventy-one patients (parts I and II) with advanced liver disease (Child-Turcotte B or C), platelet count ≥60,000/mm3 and PT in the range of 3-15 seconds above normal were included in the study. Efficacy endpoints were normalization of PT and time to hemostasis. Results: PT was corrected to normal levels (

AB - Background & Aims: Activated recombinant factor VII (rFVIIa) has been shown to be effective in correcting prolonged prothrombin time (PT) in cirrhotic patients. The main objective of this study was to evaluate the effect of 4 (5, 20, 80, and 120 μg/kg) doses of rFVIIa on correction of PT and the time to achieve hemostasis in cirrhotic patients with coagulopathy who are undergoing laparoscopic liver biopsy. Methods: Seventy-one patients (parts I and II) with advanced liver disease (Child-Turcotte B or C), platelet count ≥60,000/mm3 and PT in the range of 3-15 seconds above normal were included in the study. Efficacy endpoints were normalization of PT and time to hemostasis. Results: PT was corrected to normal levels (

UR - http://www.scopus.com/inward/record.url?scp=0036302232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036302232&partnerID=8YFLogxK

U2 - 10.1053/gast.2002.34164

DO - 10.1053/gast.2002.34164

M3 - Article

C2 - 12105840

AN - SCOPUS:0036302232

VL - 123

SP - 118

EP - 126

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -